PMP1606 (Dry Eye / Ocular Surface Inflammation) – Phase 2 Completed

A liquid suspension formulation of pimecrolimus for topical administration to the ocular surface.

A Phase 2b study has been completed in 475 dry eye patients and identified a clinically relevant and commercially attractive population that responds well to treatment. Compared to vehicle control, patients receiving pimecrolimus, demonstrated a statistically significant improvement in corneal staining and ocular discomfort versus vehicle control. Replicated in Phase 3 studies, these results meet the requirements for regulatory approval in the US and Europe. Additional background information on the asset and its anticipated competitive differentiation over marketed products can be provided on request.